Scientists described a panel of human monoclonal antibodies that neutralize clade 2.3.4.4b H5N1 hemagglutinin and provide high-resolution molecular characterization of their binding. Published in Nature Communications, the work by Alzua, León, Yellin and colleagues defines epitopes and neutralization breadth, offering candidates for therapeutic or prophylactic development against an H5N1 clade linked to zoonotic spillovers. The antibodies supply molecular tools for rapid response and may accelerate design of broadly protective influenza countermeasures.